Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Biogen's Busy Pipeline: Continued Confusion On BAN2401, But Other Irons In The Fire

Executive Summary

Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.

You may also be interested in...



Biogen To Launch Phase III Alzheimer’s Prevention Study

The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.

Clinical Trials In Review: Big Hits And Misses In 2018

Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.

United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa

It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip

Related Companies

Tags:
Latest Headlines

Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation

Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

CAR-T Safety Probe Causes Alarm, But Is Unlikely To Upend Therapies

Stock Watch: Is Oncology Still King?

See All
UsernamePublicRestriction

Register

SC124067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By